In particular, it has been demonstrated that first-line BRAF/MEK-inhibitor (BRAF/MEKi) therapy evoked complete responses (CR) in 11–19% of BRAF-mutant metastatic melanoma patients with a median PFS between 11.1–14.9 months [5,6,7]. Here, BRAF is linked to metastatic melanoma.